News from Our Members

May 16, 2017 – (Asymmetrex) – Stem cell medicine biotechnology start-up Asymmetrex will present its new contract service for adult tissue stem cell counting applications to company representatives attending Cell & Gene Exchange 2017. CGX17, the first partnering conference organized by the Alliance for Regenerative Medicine, will be attended by stem cell therapy, gene therapy, gene editing, and pharmaceutical companies, all who would benefit from Asymmetrex’s technology for counting adult tissue stem cells.
April 20, 2017 – (uniQure) – "The decision to not pursue marketing authorization renewal of Glybera in Europe involved a thoughtful and careful evaluation of patient needs and the clinical use of the therapy, and is not related to any risk-benefit concern," stated Matthew Kapusta, chief executive officer of uniQure.  "Glybera's usage has been extremely limited and we do not envision patient demand increasing materially in the years ahead."
April 11, 2017 – (Organovo) – Organovo’s board of directors has appointed Taylor J. Crouch, previously CEO of eStudySite to succeed Keith Murphy as CEO.  Mr. Murphy will remain chairman of the board, and will serve as an advisor to the Company to ensure a seamless transition and offer his counsel and expertise.
April 10, 2017 – (Mesoblast) – Mesoblast Limited (ASX: MSB; Nasdaq: MESO) announced that the Phase 3 trial of its allogeneic mesenchymal precursor cell product candidate MPC-150-IM in patients with moderate to advanced chronic heart failure was successful in the pre-specified interim futility analysis of the efficacy endpoint in the trial's first 270 patients. It is expected that the trial will enroll in total approximately 600 patients. 
April 6, 2017 – (Mesoblast) – The funds were provided to Mesoblast under the Government's R&D Tax Incentive Program, which is designed to support industry innovation.
March 30, 2017 – (Fred Hutch) – The Bezos family is offering this unprecedented gift to help Fred Hutch achieve its top strategic aim ― identifying and attracting more world-class talent to lead and propel the research priorities at the core of the Hutch’s new strategic plan.
March 30, 2017 – (Osiris) – “This novel technology developed by Osiris will benefit the entire field of cellular therapies. It is expected to accelerate development, commercialization and widespread use of living cell and tissue therapies,” said Alla Danilkovitch, Chief Scientific Officer at Osiris.

Pages